Press Releases Evaxion A/S

Equities

EVAX

US29970R3030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 14/03/2026 +04			5-day change	1st Jan Change
4.260 ^USD	+1.91%		+32.30%	-10.69%

03-13	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
03-12	European Equities Traded in US as ADRs Slump in Thursday Trading	MT

Press Releases

03-05	Evaxion A/S : Annual report 2025 (Release)	PU
03-05	Evaxion announces business update and full year 2025 financial results	AQ
03-05	Evaxion plans to file 2025 annual report later today	AQ
03-02	Evaxion to announce business update and full year 2025 financial results on March 5, 2026	AQ
01-14	Evaxion expands AI-Immunology platform into autoimmune diseases	AQ
01-13	Evaxion expands AI-Immunology™ platform into autoimmune diseases	AQ
01-07	Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week	AQ
12-19	Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2	AQ
12-06	Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting	AQ
11-20	Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1	AQ
11-12	Evaxion announce 2026 financial calendar	AQ
11-08	Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01	AQ
11-07	Evaxion A/S : Interim report Q3 2025 (Transcript)	PU
11-06	Evaxion A/S : Interim report Q3 2025 (Release)	PU
11-06	Evaxion announces business update and third quarter 2025 financial results	AQ
11-03	Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate	AQ
11-03	Correction, Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025	AQ
31/10/25	Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025	AQ
30/10/25	Evaxion raises $7.2 million, extending cash runway to second half of 2027	AQ
27/10/25	Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer	AQ
17/10/25	Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation	AQ
17/10/25	Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01	AQ
13/10/25	Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025	AQ
09/10/25	Evaxion expands AI-Immunology platform with automated vaccine design module	AQ
08/10/25	Evaxion expands AI-Immunology™ platform with automated vaccine design module	AQ